Sunesis Pharmaceuticals, Inc. has entered into a Common Shares Purchase Agreement of as much as $15.5 million with Aspire Capital Fund, LLC. Sunesis will use the proceeds for general corporate purposes, including working capital. Aspire Capital has made an initial investment in Sunesis via a purchase of $500,000 worth of common shares and has committed to purchasing up to an additional $15 million. Under the terms of the agreement, Sunesis will control the timing and amount of the further sal...